-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$0.5085.19% Upside
Lyra Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Lyra Therapeutics, Inc.?
Lyra Therapeutics, Inc. has been rated by research analysts at Jefferies in the past 90 days.